ImageneBio Posts $10.2M Q2 Loss, Cash Runway Into 2028; Lead Drug Advances
IMA sits 45% above its 52-week low of $3.94 on light trading volume (0.3× avg).
Summary
ImageneBio reported a $10.2 million net loss for Q2 2026, with $136.2 million in cash expected to fund operations into early 2028. The lead drug, olevaprubart, continues in a Phase 2b atopic dermatitis trial under an amended protocol, with topline data now expected in Q4 2027. A long-term extension study is enrolling, and a Phase 2 trial in alopecia areata is planned to start this year. The company also highlighted recent leadership additions, including a new CFO and General Counsel, and noted no safety signals from an independent data monitoring committee. The cash position and extended runway reduce near-term financing risk, but the key value driver remains clinical data years away.
At the time of this announcement, IMA was trading at $5.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4M. The 52-week trading range was $3.94 to $17.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.